Comparative Efficacy (DAS28 Remission) of Targeted Immune Modulators for Rheumatoid Arthritis: A Network Meta-Analysis
| Autor: | Andreas Karabis, Rajpal Singh, W. Reiss, Joseph Dang, Yilin Jiang, Jennie H. Best, Jennifer Uyei, Yuting Kuang |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Oncology
medicine.medical_specialty Filgotinib Remission Population Review Placebo law.invention chemistry.chemical_compound Tocilizumab Rheumatology Randomized controlled trial law Internal medicine medicine Immunology and Allergy Rheumatoid arthritis education Network meta-analysis education.field_of_study business.industry Targeted immune modulators Odds ratio medicine.disease chemistry Meta-analysis Disease activity score business |
| Zdroj: | Rheumatology and Therapy |
| ISSN: | 2198-6584 2198-6576 |
| Popis: | Introduction The objective of this study was to evaluate the relative efficacy of targeted immune modulators (TIMs) in TIM-naïve/mixed populations (≤ 20% TIM-experienced) and TIM-experienced (> 20% TIM-experienced) adults with moderate-to-severe rheumatoid arthritis with an inadequate response to or intolerance of conventional disease-modifying antirheumatic drugs (cDMARDs). Methods A fixed-effects Bayesian network meta-analysis (NMA) was performed using published study-level data from 41 randomized controlled trials (RCTs) identified from two recent systematic literature reviews conducted by the Institute for Clinical and Economic Review, and two additional phase III trials for filgotinib (FINCH-1, FINCH-2). RCTs that compared TIMs with each other, cDMARD therapy, or placebo were included. Treatments included Janus kinase (JAK) inhibitors, tumor necrosis factor α inhibitors (TNFi), and other non-TNFi therapies. Efficacy was defined as achieving remission with a DAS28 score |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|